CellCarta, a leader in precision medicine laboratory services, has acquired Biogazelle, a genomic testing expert, to enhance its capabilities in genomic analysis and expand its service offerings in high-demand therapeutic areas.

Information on the Target

CellCarta, a prominent provider of precision medicine laboratory services, announced on December 14, 2021, its acquisition of Biogazelle, a recognized leader in genomic testing solutions. Headquartered in Ghent, Belgium, Biogazelle specializes in developing and implementing advanced digital PCR (dPCR), quantitative PCR (qPCR), and RNA sequencing assays for pharmaceutical and biotechnology companies.

Biogazelle's team boasts decades of experience in gene expression analysis, positioning them as experts in the application of dPCR and qPCR technologies. Co-founders Jan Hellemans and Jo Vandesompele are internationally acclaimed for their contributions to gene expression analysis standards. Initially a spin-off from Ghent University and backed by BNP Paribas Fortis and investment funds such as Qbic, PMV, and the Fournier-Majoie Foundation, Biogazelle has been a pioneer in Europe for dPCR technology and continues to push the limits of dPCR-based research.

Industry Overview in Belgium

The biomedical and biotechnology sectors in Belgium have experienced solid growth in recent years, propelled by extensive research funding and a collaborative ecosystem among research institutions and private companies. Belgium is recognized for its strong emphasis o